|
Gimeno L, Martinez-Banaclocha H, Bernardo MV, Bolarin JM, Marin L, Lopez-Hernandez R, Lopez-Alvarez MR, Moya-Quiles MR, Muro M, Frias-Iniesta JF, Martinez-Escribano J, Alvarez-Lopez MR, Minguela A, Campillo JA. NKG2D Polymorphism in Melanoma Patients from Southeastern Spain. Cancers (Basel). 2019 Mar 28;11(4):438. doi: 10.3390/cancers11040438. PubMed PMID: 30925758; PubMed Central PMCID: PMC6521179.
AÑO: 2019; IF: 6.126
|
30925758
|
Martínez-Sánchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, Campillo JA, Bolarin JM, Bernardo MV, López-Álvarez MR, González C, García-Garay MC, Muro M, Cabañas-Perianes V, Fuster JL, García-Alonso AM, Moraleda JM, Álvarez-Lopez MR, Minguela A. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2015 Oct 29;5(4):e1093721. eCollection 2016 Apr. PubMed PMID: 27141379; PubMed Central PMCID: PMC4839374.
AÑO: 2016; IF: 7.719
|
|
Campillo JA, López-Hernández R, Martínez-Banaclocha H, Bolarín JM, Gimeno L, Mrowiec A, López M, Las Heras B, Minguela A, Moya-Quiles MR, Legáz I, Frías-Iniesta JF, García-Alonso AM, Álvarez-López MR, Martínez-Escribano JA, Muro M. MHC class I chain-related gene a diversity in patients with cutaneous malignant melanoma from southeastern Spain. Dis Markers. 2015;2015:831864. doi: 10.1155/2015/831864. PubMed PMID: 25838620; PubMed Central PMCID: PMC4370202.
AÑO: 2015; IF: 2.137
|
|
Bosch A, Llorente S, Eguia J, Mrowiec A, Boix F, López-Hernández R, Campillo JA, Salgado G, Moya-Quiles MR, Minguela A, Jimeno L, Alvarez-López MR, Muro M. HLA-C antibodies are associated with irreversible rejection in kidney transplantation: Shared molecular eplets characterization. Hum Immunol. 2014 Apr;75(4):338-41. doi: 10.1016/j.humimm.2014.01.010. PubMed PMID: 24486575.
AÑO: 2014; IF: 2.138
|
|
Boix F, Llorente S, Mrowiec A, Eguia J, López-Hernández R, Bernardo MV, Moya-Quiles MR, Campillo JA, Minguela A, Jimeno L, Alvarez-López MR, Muro M. Donor specific antibodies median fluorescence intensity levels are the best indicator for monitoring desensitization treatment in kidney transplant. Urol J. 2014 Jul 8;11(3):1695-8. PubMed PMID: 25015619.
AÑO: 2014; IF: 0.565
|